Study of PSK combination therapy aiming adverse events reduction by TS-1 in advanced gastric cancer

Phase 2

• Conditions: Gastric cancer

• Registration Number: JPRN-UMIN000003372
• Lead Sponsor: Kansai Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-01
• Study Completion: 2012-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Not provided

Exclusion Criteria

1)Schronous, mtaschronous double cancer/ multiple cancer 2)administration contraindication of TS-1 (refer package insert) 3)Regular use of flucytosine, phenytoin or warfarin potassium 4)History of severe drug allergy (grade 3>=) 5)Severe complications such as paralytic ileus, bowel obstruction, interstitial pneumonitis or pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure and hepatic failure etc. 6)Severe watery diarrhea 7)Pregnancy or lactation 8)Male intension that get with child 9)HIV positive 10)Patients who are recognized as inadequate patients by doctors whit responsibility in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified